- STAT+: Drug companies, patient groups urge FDA to pause commissioner’s voucher programThe White House has used the program to reward companies that help its political goals.STAT · 1mo ago↗ source
- What RevMed’s pancreatic cancer drug meant for one patientWhy did a presentation on Revolution Medicines' pancreatic cancer drug get a standing ovation? Why did biotech stocks perform so badly this week? Find out on "The Readout LOUD."STAT · 1mo ago↗ source
- STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trialOtsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.